Quinaprilat (Synonyms: CI-928) |
رقم الكتالوجGC52034
One-Click Copy Product Info
|
Quinaprilat هو مثبط إنزيم محول للأنجيوتنسين غير مركابتو نشط عن طريق الفم ، وهو المستقلب النشط لـ Quinapril
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 82768-85-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Quinaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50 = 0.06 nM) and an active metabolite of the ACE inhibitor prodrug quinapril .1,2 It inhibits calcium overload and rod to round cell shape change induced by lysophosphatidylcholine (LPC) in isolated rat cardiomyocytes when used at concentrations of 20 and 50 µM.2 Quinaprilat (3 µg/kg) reduces the frequency of ventricular fibrillation in a dog model of myocardial ischemia and reperfusion injury.3 It also reduces blood pressure and proteinuria in rat models of uranyl nitrate- or 5/6 nephrectomy-induced chronic renal failure when administered at a dose of 0.1 mg/kg.4
1.Perich, R.B., Jackson, B., and Johnston, C.I.Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzymeEur. J. Pharmacol.266(3)201-211(1994) 2.Ma, H., Hashizume, H., Hara, A., et al.Protective effect of quinaprilat, an active metabolite of quinapril, on Ca2+-overload induced by lysophosphatidylcholine in isolated rat cardiomyocytesJpn. J. Pharmacol.79(1)17-24(1999) 3.Fujinaga, H., Wakatsuki, T., Nishikado, A., et al.Electrophysiologic effects of quinaprilat in dogs during acute myocardial ischemia and following reperfusionCoron. Artery Dis.9(10)697-701(1998) 4.Appenroth, D., Beutinger, R., Lupp, A., et al.Effects of a therapy with losartan and quinaprilat on the progression of chronic renal failure in rats after a single dose of uranyl nitrate or 5/6 nephrectomyExp. Toxicol. Pathol.54(5-6)359-366(2003)
| Cas No. | 82768-85-2 | SDF | |
| المرادفات | CI-928 | ||
| Canonical SMILES | OC([C@H](CCC1=CC=CC=C1)N[C@@H](C)C(N2[C@@H](CC3=CC=CC=C3C2)C(O)=O)=O)=O | ||
| Formula | C23H26N2O5 | M.Wt | 410.5 |
| الذوبان | DMSO: Slightly soluble,Methanol: Slightly soluble | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4361 mL | 12.1803 mL | 24.3605 mL |
| 5 mM | 487.2 μL | 2.4361 mL | 4.8721 mL |
| 10 mM | 243.6 μL | 1.218 mL | 2.4361 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >90.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)